New York – February 28, 2019 – Creative Biolabs, a biology company engaged in cancer immunotherapies, recently announces its comprehensive chimeric antigen receptors design and construction services.
As novel cancer immunotherapy, CAR T therapy has overcome the limitations of conventional cancer treatment (surgery, chemotherapy, and radiation therapy) against multiple human malignancies. CAR refers to chimeric antigen receptor or artificial T cell receptor, which is engineered elaborately and endowing an immune effector cell (T cell) with an arbitrary specificity via a monoclonal antibody.
So far through years of CAR-T Cell Development, four generations of CAR have been developed for cancer treatment, which are all available in Creative Biolabs’ services listing. The first-generation CAR, consisting of the intracellular domain from the CD3 ζ- chain and the primary transmitter of signals from endogenous TCRs, showed success in pre-clinical trials and entered Phase I clinical trials in ovarian cancer, neuroblastoma and various types of leukemia and lymphoma. It is also the most common form of CARs to fuse single-chain variable fragments (scFv) derived from monoclonal antibodies to CD3 ζ transmembrane and endo domain. Then the 2nd-generation CARs were designed to augment the antitumor efficacy of 1st-generation CARs, by combining the intracellular signaling domains from various costimulatory protein receptors incorporated in the cytoplasmic tail of the CAR to enhance the signaling. As the expectation of more antitumor efficacy, the 3rd-generation of CARs combined multiple signaling domains to acquire further enhanced activation signals, proliferation, production of cytokines and effective function.
“Despite the high specificity and superior ability of previous CAR-T generations to redirect T cells targeting malicious cancer cells, there remains a major limitation due to antigen-negative cancer cells on solid tumors with a tremendous phenotypic heterogeneity and relapse to trigger a novel CAR strategy. At last, the 4th-generation CAR-T is designed to shape the tumor environment by the inducible release of transgenic immune modifiers, such as IL-12, which augments T-cell activation, attracts and activates innate immune cells to eliminate antigen-negative cancer cells in the targeted lesion. Based on years of research on CAR-T therapy, our team can customize the CAR design and construction of all four generations,” said a scientist in Creative Biolabs.
“On the other hand, besides the classical route of CARs, more and more special CARs are designed and undergo intensive research such as TanCAR, physiological CAR (receptor/ligand-based), universal CAR (biotin/avidin-based), VHH-based CAR, CAR-macrophage, CAR-modified NK cells, γδ CAR-T, etc.”
More information on special CAR design and construction can be reached at https://www.creative-biolabs.com/car-t.
About Creative Biolabs
As a global company, Creative Biolabs has more than 200 talented and well-trained scientists located in different continents working closely with partners from the entire world to develop and produce medicines of tomorrow. Specifically, the established leading experts in TCR and CAR T&NK cell immune therapy development offer the one-stop custom services that cover the entire new drug development pipeline, and an exclusive line of ready-to-use TCR and CAR T&NK cell construction products, such as virus packaging, purification, expansion and titer determination kits. Furthermore, a unique unparalleled CAR construction and production platform has been built up for all four CAR generations.
Media ContactCompany Name: Creative BiolabsContact Person: Candy SwiftEmail: Send EmailPhone: 1-631-619-7922Address:45-1 Ramsey Road City: ShirleyState: New YorkCountry: United StatesWebsite: www.creative-biolabs.com/car-t
